Immune-Tolerant Hepatitis B Infection: To Treat or Not to Treat?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Despite a decline in the annual incidence of hepatitis B virus (HBV) infection following the implementation of routine vaccination, a significant number of children remain infected. Unlike the infected adult population, who often demonstrate clinical symptoms or abnormalities on routine laboratory investigations, children are often silently infected due to immune tolerance to the virus. Few studies have addressed treatment of these immune-tolerant children because they are not believed to be at a high risk for developing disease sequela during this phase of infection. Although there remain several important unanswered questions, routine treatment of children in the immune-tolerant phase of HBV infection is not currently recommended.
- Sorrell MF, Belongia EA, Costa J, et al.: National institutes of health consensus development conference statement: management of hepatitis B. Ann Intern Med 2009, 150:104–110.
- Fwu CW, Chien YC, Kirk GD, et al.: Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J Natl Cancer Inst 2009, 101:1019–1027. CrossRef
- Centers for Disease Control and Prevention: Epidemiology and Prevention of Vaccine-Preventable Diseases, edn 11. Edited by Atkinson W, Wolfe S, Hamborsky J, McIntyre L. Washington DC: Public Health Foundation; 2009.
- Fattovich G, Olivari N, Pasino M, et al.: Long-term outcome of chronic hepatitis B in caucasian patients: mortality after 25 years. Gut 2008, 57:84–90. CrossRef
- Weinbaum CM, Williams I, Mast EE, et al.: Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008, 57:1–20.
- Ribeiro RM, Lo A, Perelson AS: Dynamics of hepatitis B virus infection. Microbes Infect 2002, 4:829–835. CrossRef
- Koff RS, Slavin MM, Connelly JD, Rosen DR: Contagiousness of acute hepatitis B. secondary attack rates in household contacts. Gastroenterology 1977, 72:297–300.
- Pungpapong S, Kim WR, Poterucha JJ: Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 2007, 82:967–975. CrossRef
- Hyams KC: Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995, 20:992–1000.
- Chang MH, Hsu HY, Hsu HC, et al.: The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology 1995, 22:1387–1392.
- Hui CK, Leung N, Yuen ST, et al.: Natural history and disease progression in chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007, 46:395–401. CrossRef
- Dienstag JL: Hepatitis B virus infection. N Engl J Med 2008, 359:1486–1500. CrossRef
- Shah U, Kelly D, Chang MH, et al.: Management of chronic hepatitis B in children. J Pediatr Gastroenterol Nutr 2009, 48:399–404. CrossRef
- Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009, 50:661–662. CrossRef
- Chien RN, Liaw YF, Atkins M: Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian hepatitis lamivudine trial group. Hepatology 1999, 30:770–774. CrossRef
- Lai CL, Lin HJ, Lau JN, et al.: Effect of recombinant alpha 2 interferon with or without prednisone in chinese HBsAg carrier children. Q J Med 1991, 78:155–163.
- • D’Antiga L, Aw M, Atkins M, et al.: Combined lamivudine/interferon-alpha treatment in "immunotolerant" children perinatally infected with hepatitis B: a pilot study. J Pediatr 2006, 148:228–233. This pilot study is the only one in current literature that address the effectiveness of combination therapy in immune-tolerant children. CrossRef
- Gregorio GV, Jara P, Hierro L, et al.: Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology 1996, 23:700–707. CrossRef
- Sherman M: Predicting survival in hepatitis B. Gut 2005, 54:1521–1523.
- Chen CJ, Yang HI, Su J, et al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65–73. CrossRef
- Iloeje UH, Yang HI, Su J, et al.: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678–686. CrossRef
- • Haber BA, Block JM, Jonas MM, et al.: Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B. Pediatrics 2009, 124:e1007–e1013. This article summarizes the current expert recommendations for HBV treatment in children. CrossRef
- Immune-Tolerant Hepatitis B Infection: To Treat or Not to Treat?
Current Hepatitis Reports
Volume 9, Issue 2 , pp 60-64
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Hepatitis B virus
- Natural history
- Immune tolerant
- Industry Sectors